Antibody therapeutics

Keyphrases

Publications

volume 7, number 1, 2024

Feiyan Deng, Yuxin Qiu, Xiangling Zhang, Nining Guo, Junhong Hu, Wenjie Yang, Wei Shang, Bicheng Liu, Suofu Qin
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy. Antibody therapeutics 7 (1) (2024)
Kee Wee Tan, Pengfei Ji, Hang Zhou, Sam Zhang, Weichang Zhou
Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs. Antibody therapeutics 7 (1) (2024)
Hui Chen, Sung-Jin Lee, Brian Ouyang, Nicholas Suen, Jay Ye, Chenggang Lu, Yang Li
Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies. Antibody therapeutics 7 (1) (2024)
Hui Chen, Sung-Jin Lee, Brian Ouyang, Nicholas Suen, Jay Ye, Chenggang Lu, Yang Li
Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies. Antibody therapeutics 7 (1) (2024)
Feiyan Deng, Yuxin Qiu, Xiangling Zhang, Nining Guo, Junhong Hu, Wenjie Yang, Wei Shang, Bicheng Liu, Suofu Qin
GB12-09, a bispecific antibody targeting IL4Rα and IL31Rα for atopic dermatitis therapy. Antibody therapeutics 7 (1) (2024)
Kee Wee Tan, Pengfei Ji, Hang Zhou, Sam Zhang, Weichang Zhou
Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs. Antibody therapeutics 7 (1) (2024)

volume 7, number 2, 2024

Xiaojie Ma, Mingkai Wang, Tianlei Ying, Yanling Wu
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate. Antibody therapeutics 7 (2) (2024)
Yuanzhi Chen, Zhiren Zeng, Ziyou Chen, Na Yuan, Xinya Ye, Chengcheng Zhang, Ning-Shao Xia, Wenxin Luo
A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains. Antibody therapeutics 7 (2) (2024)
Xiaolei Liu, Jianzhong Han, Qian Wang, Peng Wang, Li Li, Kehe Du, Fengchao Jiang, Pei Zhang, Hongjun Liu, Jian Huang
Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. Antibody therapeutics 7 (2) (2024)
Xiaolei Liu, Jianzhong Han, Qian Wang, Peng Wang, Li Li, Kehe Du, Fengchao Jiang, Pei Zhang, Hongjun Liu, Jian Huang
Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. Antibody therapeutics 7 (2) (2024)
Satoru Kawakita, Aidan Shen, Cheng-Chi Chao, Zhaohui Wang, Siliangyu Cheng, Bingbing Li, Chongming Jiang
An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy. Antibody therapeutics 7 (2) (2024)
Xiaojie Ma, Mingkai Wang, Tianlei Ying, Yanling Wu
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate. Antibody therapeutics 7 (2) (2024)
Marisa L Yang, Tom Z Yuan, Kara Y Chan, Lin Ding, Zhen Han, Hector Franco, Carson Holliday, Shruthi Kannan, Edgar Davidson, Benjamin J Doranz, Kartik Chandran, Emily Happy Miller, Jessica A Plante, Scott C Weaver, Eunice Cho, Shweta Kailasan, Lukas Marsalek, Hoa Giang, Yasmina Abdiche, Aaron K Sato
A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants. Antibody therapeutics 7 (2) (2024)
William R Strohl
Structure and function of therapeutic antibodies approved by the US FDA in 2023. Antibody therapeutics 7 (2) (2024)
Anhye Kim, Min-Seok Oh, Gwan-Ho Lee, Seongeun Song, Mi-Sun Byun, Donghoon Choi, Byung-Yong Yu, Howard Lee
Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA. Antibody therapeutics 7 (2) (2024)
Marisa L Yang, Tom Z Yuan, Kara Y Chan, Lin Ding, Zhen Han, Hector Franco, Carson Holliday, Shruthi Kannan, Edgar Davidson, Benjamin J Doranz, Kartik Chandran, Emily Happy Miller, Jessica A Plante, Scott C Weaver, Eunice Cho, Shweta Kailasan, Lukas Marsalek, Hoa Giang, Yasmina Abdiche, Aaron K Sato
A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants. Antibody therapeutics 7 (2) (2024)
Xiaojie Ma, Mingkai Wang, Tianlei Ying, Yanling Wu
Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate. Antibody therapeutics 7 (2) (2024)
Anhye Kim, Min-Seok Oh, Gwan-Ho Lee, Seongeun Song, Mi-Sun Byun, Donghoon Choi, Byung-Yong Yu, Howard Lee
Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA. Antibody therapeutics 7 (2) (2024)
William R Strohl
Structure and function of therapeutic antibodies approved by the US FDA in 2023. Antibody therapeutics 7 (2) (2024)
Yuanzhi Chen, Zhiren Zeng, Ziyou Chen, Na Yuan, Xinya Ye, Chengcheng Zhang, Ning-Shao Xia, Wenxin Luo
A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains. Antibody therapeutics 7 (2) (2024)
Satoru Kawakita, Aidan Shen, Cheng-Chi Chao, Zhaohui Wang, Siliangyu Cheng, Bingbing Li, Chongming Jiang
An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy. Antibody therapeutics 7 (2) (2024)
William R Strohl
Structure and function of therapeutic antibodies approved by the US FDA in 2023. Antibody therapeutics 7 (2) (2024)

volume 7, number 3, 2024

Shuang Wang, Weijie Zhang, Baotian Yang, Xudong Zhang, Jing Fang, Haopeng Rui, Zhijian Chen, Jijie Gu, Zhiqiang Chen, Jianqing Xu
A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications. Antibody therapeutics 7 (3) (2024)
Shuang Wang, Weijie Zhang, Baotian Yang, Xudong Zhang, Jing Fang, Haopeng Rui, Zhijian Chen, Jijie Gu, Zhiqiang Chen, Jianqing Xu
A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications. Antibody therapeutics 7 (3) (2024)
Xiaofeng Niu, Chunnian Wang, Haixia Jiang, Rui Gao, Yefeng Lu, Xiaoli Guo, Hongping Zhou, Xue Cui, Jun Sun, Quan Qiu, Dawei Sun, Hongtao Lu
A pan-allelic human SIRPα-blocking antibody, ES004-B5, promotes tumor killing by enhancing macrophage phagocytosis and subsequently inducing an effective T-cell response. Antibody therapeutics 7 (3) (2024)
Yang Wang, Bing Xia, Lixia Cao, Jianfeng Yang, Cui Feng, Fangdun Jiang, Chen Li, Lixia Gu, Yifan Yang, Jing Tian, Xin Cheng, Keiji Furuuchi, James Fulmer, Arielle Verdi, Katherine Rybinski, Allis Soto, Earl Albone, Toshimitsu Uenaka, Likun Gong, Tingting Liu, Qiuping Qin, Ziping Wei, Yuhong Zhou
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity. Antibody therapeutics 7 (3) (2024)
Xinya Ye, Xiaoqing Chen, Han Liu, Yichao Jiang, Chengyu Yang, Tao Xu, Ziyou Chen, Yalin Wang, Fentian Chen, Xue Liu, Hai Yu, Quan Yuan, Ningshao Xia, Yuanzhi Chen, Wenxin Luo
HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study. Antibody therapeutics 7 (3) (2024)
Yang Wang, Bing Xia, Lixia Cao, Jianfeng Yang, Cui Feng, Fangdun Jiang, Chen Li, Lixia Gu, Yifan Yang, Jing Tian, Xin Cheng, Keiji Furuuchi, James Fulmer, Arielle Verdi, Katherine Rybinski, Allis Soto, Earl Albone, Toshimitsu Uenaka, Likun Gong, Tingting Liu, Qiuping Qin, Ziping Wei, Yuhong Zhou
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity. Antibody therapeutics 7 (3) (2024)
Xin Yu, Kostika Vangjeli, Anusha Prakash, Meha Chhaya, Samantha J Stanley, Noah Cohen, Lili Huang
Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies. Antibody therapeutics 7 (3) (2024)
Xin Yu, Kostika Vangjeli, Anusha Prakash, Meha Chhaya, Samantha J Stanley, Noah Cohen, Lili Huang
Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies. Antibody therapeutics 7 (3) (2024)
Yang Wang, Bing Xia, Lixia Cao, Jianfeng Yang, Cui Feng, Fangdun Jiang, Chen Li, Lixia Gu, Yifan Yang, Jing Tian, Xin Cheng, Keiji Furuuchi, James Fulmer, Arielle Verdi, Katherine Rybinski, Allis Soto, Earl Albone, Toshimitsu Uenaka, Likun Gong, Tingting Liu, Qiuping Qin, Ziping Wei, Yuhong Zhou
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity. Antibody therapeutics 7 (3) (2024)
Zening Wang, Minhyo Kang, Afshin Ebrahimpour, Chuan Chen, Xin Ge
Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs. Antibody therapeutics 7 (3) (2024)
Sowmya Ramaswamy Krishnan, Divya Sharma, Yasin Nazeer, Mayilvahanan Bose, Thangarajan Rajkumar, Guhan Jayaraman, Narayanan Madaboosi, M Michael Gromiha
rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering. Antibody therapeutics 7 (3) (2024)
Michael E Dolan, Amissi Sadiki, Leo Lei Wang, Yan Wang, Christopher Barton, Sheldon F Oppenheim, Zhaohui Sunny Zhou
First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region. Antibody therapeutics 7 (3) (2024)
Yang Wang, Bing Xia, Lixia Cao, Jianfeng Yang, Cui Feng, Fangdun Jiang, Chen Li, Lixia Gu, Yifan Yang, Jing Tian, Xin Cheng, Keiji Furuuchi, James Fulmer, Arielle Verdi, Katherine Rybinski, Allis Soto, Earl Albone, Toshimitsu Uenaka, Likun Gong, Tingting Liu, Qiuping Qin, Ziping Wei, Yuhong Zhou
Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity. Antibody therapeutics 7 (3) (2024)
Zening Wang, Minhyo Kang, Afshin Ebrahimpour, Chuan Chen, Xin Ge
Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs. Antibody therapeutics 7 (3) (2024)

volume 7, number 1, 2023

Mohamed A Alfaleh, Reem M Alsulaiman, Sarah A Almahboub, Leena Nezamuldeen, Ayat Zawawi, Najwa D Aljehani, Muhammad Yasir, Rwaa H Abdulal, Rami Alkhaldi, Assala Helal, Sawsan S Alamri, Jana Malki, Rowa Y Alhabbab, Turki S Abujamel, Nabil A Alhakamy, Aisha Alnami, Abdullah Algaissi, Mazen Hassanain, Anwar M Hashem
ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks. Antibody therapeutics 7 (1) (2023)
Xiaozhang Zhang, Ningning Zhou, Chunsheng Yang, Zhaowei Jin, Jeremy Guo
Multiple approaches to reduce reconstitution time of lyophilized drug products with high protein concentration. Antibody therapeutics 7 (1) (2023)
Xiaozhang Zhang, Ningning Zhou, Chunsheng Yang, Zhaowei Jin, Jeremy Guo
Multiple approaches to reduce reconstitution time of lyophilized drug products with high protein concentration. Antibody therapeutics 7 (1) (2023)
Mohamed A Alfaleh, Reem M Alsulaiman, Sarah A Almahboub, Leena Nezamuldeen, Ayat Zawawi, Najwa D Aljehani, Muhammad Yasir, Rwaa H Abdulal, Rami Alkhaldi, Assala Helal, Sawsan S Alamri, Jana Malki, Rowa Y Alhabbab, Turki S Abujamel, Nabil A Alhakamy, Aisha Alnami, Abdullah Algaissi, Mazen Hassanain, Anwar M Hashem
ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks. Antibody therapeutics 7 (1) (2023)
Songna Wang, Pinliang Hu, Jiajun Fan, Jing Zou, Weidong Hong, Xuan Huang, Danjie Pan, Huaning Chen, Yi Zhun Zhu, Li Ye
CD80-Fc fusion protein as a potential cancer immunotherapy strategy. Antibody therapeutics 7 (1) (2023)
Shuo Tang, Jiaoli Tao, Ying Li
Challenges and solutions for the downstream purification of therapeutic proteins. Antibody therapeutics 7 (1) (2023)
Daniel Keri, Matt Walker, Isha Singh, Kyle Nishikawa, Fernando Garces
Next generation of multispecific antibody engineering. Antibody therapeutics 7 (1) (2023)
Shuo Tang, Jiaoli Tao, Ying Li
Challenges and solutions for the downstream purification of therapeutic proteins. Antibody therapeutics 7 (1) (2023)
Joshua W Morse, Xun Gui, Mi Deng, Ryan Huang, Xiaohua Ye, Peng Zhao, Xuejun Fan, Wei Xiong, Chengcheng Zhang, Ningyan Zhang, Zhiqiang An
Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML. Antibody therapeutics 7 (1) (2023)
Joshua W Morse, Xun Gui, Mi Deng, Ryan Huang, Xiaohua Ye, Peng Zhao, Xuejun Fan, Wei Xiong, Chengcheng Zhang, Ningyan Zhang, Zhiqiang An
Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML. Antibody therapeutics 7 (1) (2023)
Songna Wang, Pinliang Hu, Jiajun Fan, Jing Zou, Weidong Hong, Xuan Huang, Danjie Pan, Huaning Chen, Yi Zhun Zhu, Li Ye
CD80-Fc fusion protein as a potential cancer immunotherapy strategy. Antibody therapeutics 7 (1) (2023)
Joshua W Morse, Xun Gui, Mi Deng, Ryan Huang, Xiaohua Ye, Peng Zhao, Xuejun Fan, Wei Xiong, Chengcheng Zhang, Ningyan Zhang, Zhiqiang An
Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML. Antibody therapeutics 7 (1) (2023)
Daniel Keri, Matt Walker, Isha Singh, Kyle Nishikawa, Fernando Garces
Next generation of multispecific antibody engineering. Antibody therapeutics 7 (1) (2023)
Joshua W Morse, Xun Gui, Mi Deng, Ryan Huang, Xiaohua Ye, Peng Zhao, Xuejun Fan, Wei Xiong, Chengcheng Zhang, Ningyan Zhang, Zhiqiang An
Fc gamma receptors promote antibody-induced LILRB4 internalization and immune regulation of monocytic AML. Antibody therapeutics 7 (1) (2023)